DAY 0
(Continued)
(Continued)
Aspergillus detected and Liposomal Amphotericin
B treatment initiated*
B treatment initiated*
*Please refer to the Summary of Product Characteristics of your chosen treatment prior to prescribing.
**Administration of a test dose is advisable before a new course of Liposomal Amphotericin B treatment.
Therapy is usually instituted at a daily dose of 1.0 mg/kg of body weight and increased stepwise to 3.0
mg/kg as required. Data are presently insufficient to define total dosage requirements and duration of
treatment necessary for resolution of mycoses. Dosage of amphotericin B as Liposomal Amphotericin B
must be adjusted to the specific requirements of each patient.6
**Administration of a test dose is advisable before a new course of Liposomal Amphotericin B treatment.
Therapy is usually instituted at a daily dose of 1.0 mg/kg of body weight and increased stepwise to 3.0
mg/kg as required. Data are presently insufficient to define total dosage requirements and duration of
treatment necessary for resolution of mycoses. Dosage of amphotericin B as Liposomal Amphotericin B
must be adjusted to the specific requirements of each patient.6
A result demonstrating the presence of
Aspergillus was obtained from a lateral flow
device test on the bronchoalveolar lavage
(BAL) respiratory sample.
Aspergillus was obtained from a lateral flow
device test on the bronchoalveolar lavage
(BAL) respiratory sample.
As a result, treatment with Liposomal
Amphotericin B was initiated at a dose of
3 mg/kg/day.**
Amphotericin B was initiated at a dose of
3 mg/kg/day.**
Decision point
Why Liposomal Amphotericin B
Results
